Literature DB >> 3260204

Effects of recombinant interleukin 2 on immunological effector cells of the peripheral blood in patients with HBe antigen-positive chronic hepatitis.

Y Mizoguchi1, T Shin, Y Sakagami, S Seki, T Kuroki, K Kobayashi, S Yamamoto, S Morisawa.   

Abstract

Changes in peripheral blood immunological effector cells after systemic administration of recombinant interleukin 2 (rIL2) were studied in 14 patients with HBe antigen-positive chronic hepatitis. The patients were intravenously injected with rIL2 for 4 weeks, and the experiments were performed using mononuclear cells isolated from the peripheral blood during and after rIL2 administration. No significant changes in OKT4-positive cell population, OKT8-positive cell population, OKT4/OKT8 ratio and Leu7-positive cell population were detected during and after intravenous injection of rIL2. However, the natural killer (NK) cell and lymphokine-activated killer (LAK) cell activities significantly increased in the fourth week of rIL2 administration, while the K cell activity in the antibody-dependent cell-mediated cytotoxicity reaction, antibody response, lectin-induced lymphocyte transformation and IL1 production of LPS-stimulated monocytes were not affected. These results suggest that IL2 increases the NK cell and LAK cell activities in vivo.

Entities:  

Mesh:

Substances:

Year:  1988        PMID: 3260204     DOI: 10.1007/bf02799026

Source DB:  PubMed          Journal:  Gastroenterol Jpn        ISSN: 0435-1339


  17 in total

Review 1.  Cytotoxic effects of lymphoid cells in vitro.

Authors:  P Perlmann; G Holm
Journal:  Adv Immunol       Date:  1969       Impact factor: 3.543

2.  Translation of interleukin 2 mRNA from human peripheral blood leukocytes in Xenopus oocytes.

Authors:  S Hinuma; H Onda; K Naruo; Y Ichimori; M Koyama; K Tsukamoto
Journal:  Biochem Biophys Res Commun       Date:  1982-11-30       Impact factor: 3.575

3.  Interleukin 2 dependence of human natural killer (NK) cell activity.

Authors:  W Domzig; B M Stadler; R B Herberman
Journal:  J Immunol       Date:  1983-04       Impact factor: 5.422

4.  Lymphokine-activated killer cells: lysis of fresh syngeneic natural killer-resistant murine tumor cells by lymphocytes cultured in interleukin 2.

Authors:  M Rosenstein; I Yron; Y Kaufmann; S A Rosenberg
Journal:  Cancer Res       Date:  1984-05       Impact factor: 12.701

5.  In vivo administration of purified human interleukin 2. I. Half-life and immunologic effects of the Jurkat cell line-derived interleukin 2.

Authors:  M T Lotze; L W Frana; S O Sharrow; R J Robb; S A Rosenberg
Journal:  J Immunol       Date:  1985-01       Impact factor: 5.422

6.  T cell factor (interleukin 2) allows in vivo induction of T helper cells against heterologous erythrocytes in athymic (nu/nu) mice.

Authors:  H Stötter; E Rüde; H Wagner
Journal:  Eur J Immunol       Date:  1980-09       Impact factor: 5.532

7.  A new approach to the adoptive immunotherapy of cancer with tumor-infiltrating lymphocytes.

Authors:  S A Rosenberg; P Spiess; R Lafreniere
Journal:  Science       Date:  1986-09-19       Impact factor: 47.728

8.  Systemic administration of recombinant human interleukin-2 in mice.

Authors:  A E Chang; C L Hyatt; S A Rosenberg
Journal:  J Biol Response Mod       Date:  1984-10

9.  Plaque Formation in Agar by Single Antibody-Producing Cells.

Authors:  N K Jerne; A A Nordin
Journal:  Science       Date:  1963-04-26       Impact factor: 47.728

10.  Activation of virus specific CTL clones: antigen-dependent regulation of interleukin 2 receptor expression.

Authors:  M E Andrew; A M Churilla; T R Malek; V L Braciale; T J Braciale
Journal:  J Immunol       Date:  1985-02       Impact factor: 5.422

View more
  1 in total

1.  Sequential combination therapy with interferon, interleukin-2 and therapeutic vaccine in entecavir-suppressed chronic hepatitis B patients: the Endeavor study.

Authors:  Di Wu; Peng Wang; Meifang Han; Yongping Chen; Xinyue Chen; Qi Xia; Weiming Yan; Xiaoyang Wan; Chuanlong Zhu; Qing Xie; Jiaji Jiang; Lai Wei; Deming Tan; Xiaoguang Dou; Yanyan Yu; Jinlin Hou; Xiaoping Luo; Qin Ning
Journal:  Hepatol Int       Date:  2019-06-06       Impact factor: 6.047

  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.